Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Total Assets
Latest total assets as of September 2025: CN¥2.80 Billion CNY
Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) holds total assets worth CN¥2.80 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hainan Huluwa Pharmaceutical Group Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hainan Huluwa Pharmaceutical Group Co Ltd's total assets of CN¥2.80 Billion consist of 41.1% current assets and 58.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.6% |
| Accounts Receivable | CN¥419.55 Million | 14.2% |
| Inventory | CN¥446.77 Million | 15.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥272.95 Million | 9.2% |
| Goodwill | CN¥12.11 Million | 0.4% |
Asset Composition Trend (2016–2024)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Huluwa Pharmaceutical Group Co Ltd's current assets represent 41.1% of total assets in 2024, an increase from 41.1% in 2016.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2024, down from 11.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 20.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 15.1% of total assets.
Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Hainan Huluwa Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hainan Huluwa Pharmaceutical Group Co Ltd generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hainan Huluwa Pharmaceutical Group Co Ltd is currently not profitable relative to its asset base.
Hainan Huluwa Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 1.05 | 1.76 |
| Quick Ratio | 0.56 | 0.75 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-230.42 Million | CN¥ 60.20 Million | CN¥ 415.11 Million |
Hainan Huluwa Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hainan Huluwa Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.89 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -3.1% |
| Total Assets | CN¥2.96 Billion |
| Market Capitalization | $137.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Huluwa Pharmaceutical Group Co Ltd's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hainan Huluwa Pharmaceutical Group Co Ltd's assets decreased by 3.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2024)
The table below shows the annual total assets of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.96 Billion | -3.14% |
| 2023-12-31 | CN¥3.06 Billion | +32.37% |
| 2022-12-31 | CN¥2.31 Billion | +31.30% |
| 2021-12-31 | CN¥1.76 Billion | +15.76% |
| 2020-12-31 | CN¥1.52 Billion | +39.99% |
| 2019-12-31 | CN¥1.09 Billion | -0.49% |
| 2018-12-31 | CN¥1.09 Billion | +35.28% |
| 2017-12-31 | CN¥807.21 Million | +50.61% |
| 2016-12-31 | CN¥535.95 Million | -- |